GB2616177A - Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof - Google Patents
Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof Download PDFInfo
- Publication number
- GB2616177A GB2616177A GB2308366.0A GB202308366A GB2616177A GB 2616177 A GB2616177 A GB 2616177A GB 202308366 A GB202308366 A GB 202308366A GB 2616177 A GB2616177 A GB 2616177A
- Authority
- GB
- United Kingdom
- Prior art keywords
- plgf
- cells
- monoclonal antibody
- mice
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 47
- 241000699670 Mus sp. Species 0.000 claims description 36
- 230000007910 cell fusion Effects 0.000 claims description 19
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 16
- 206010003445 Ascites Diseases 0.000 claims description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
- 238000010367 cloning Methods 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- 238000003113 dilution method Methods 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 claims description 7
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 7
- 238000003163 cell fusion method Methods 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000003393 splenic effect Effects 0.000 claims description 5
- 102100035194 Placenta growth factor Human genes 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000010899 nucleation Methods 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 101150062285 PGF gene Proteins 0.000 claims description 3
- 101710120037 Toxin CcdB Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000003450 affinity purification method Methods 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000000689 upper leg Anatomy 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 2
- 239000003102 growth factor Substances 0.000 abstract description 2
- 210000002826 placenta Anatomy 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract 1
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000009206 Abruptio Placentae Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010054810 Placental dysplasia Diseases 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 102000056450 human PIGF Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 201000008532 placental abruption Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Abstract
Provided are a hybridoma cell strain 9C1, a PLGF-1 monoclonal antibody, a preparation method therefor and an application thereof. The PLGF-1 monoclonal antibody is secreted by the monoclonal antibody hybridoma cell strain 9C1 collected in China center for type culture collection (CCTCC) on 11 September 2019 and having the collection number of CCTCC NO:C2019216. The monoclonal antibody prepared for a PLGF-1 recombinant protein has higher specificity and sensitivity to a PLGF-1 antigen, lays a foundation for functional research and development of placenta growth factors and the development of corresponding diagnostic reagents.
Description
HYBRIDOMA CELL STRAIN 9C1, PLGF-1 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
FIELD OF THE PRESENT DISCLOSURE
[0001] The present invention relates to the field of bioengineering, in particular to a hybridoma cell strain 9C1, a PLGF-1 monoclonal antibody, a preparation method therefor and application thereof.
BACKGROUND
[0002] During remodeling of uterine spiral artery, syncytiotrophoblast cells secrete placental growth factors (PLGF-1), which promotes angiogenesis and improves blood perfusion. In normal pregnancy, the serum level of PLGF-1 in healthy pregnant women is low during pregnancy week 5-15, and the expression of PLGF-1 increases rapidly within week 15-26, then reaches a peak at week 28-30. Afterwards, with the gradual maturing and aging of the placenta, the PLGF-1 level decreases significantly The significant reduction of the PLGF-1 level in the presence of placentation defects will result in placental dysplasia, causing placental insufficiency, so it is difficult to provide sufficient nutrients and oxygen to the fetus, which may lead to a series of diseases, such as miscarriage, gestational hypertension, preeclampsia (PE), fetal growth restriction and premature birth, etc., and in severe cases, also may lead to related complications, such as stillbirth, eclampsia, HELLP syndromes and placental abruption.
Compared with the traditional diagnosis methods, the decrease of PLGF-1 concentration occurs 9-11 weeks earlier than the arising of hypertension and proteinuria, and is mainly demonstrated in the concentration within five weeks before the disease onset.
[0003] At present, the methods for PLGF-1 detection include enzyme-linked immunosorbent assay and microfluidic fluorescence immunoassay, while high requirements for the relevant detection antibodies have been put forward due to the low concentration of PLGF-1 in serum. Therefore, it is urgent to develop an anti-human placental growth factor-1 antibody that can be detected rapidly and sensitively, and is promising to be used in clinical diagnosis.
SUMMARY
[0004] An object of the present invention is to provide a hybridoma cell strain 9C1, which is collected in China Center for Type Culture Collection (CCTCC) (Address: Wuhan University in Wuhan, China) on September 11, 2019 with a collection number of CCTCC NO: C2019216.
[0005] A further object of the present invention is to provide a monoclonal antibody of human placental growth factor-1, i.e., a PLGF-1 monoclonal antibody, secreted by the hybridoma cell strain 9C1(collection number, CCTCC NO: C2019216), wherein the heavy chain has the amino acid sequence shown in SEQ ID NO.1 of the sequence listing, and the light chain has the amino acid sequence shown in SEQ ID NO.2. The subtype of the monoclonal antibody is IgG1, K. [0006] Another object of the present invention is to provide a use of the hybridoma cell strain 9C1 in the preparation of a PLGF-1 monoclonal antibody [0007] Still another object of the present invention is to provide a detection reagent comprising the PLGF-1 monoclonal antibody [0008] Yet another object of the present invention is to provide a preparation method for the PLGF-1 monoclonal antibody which comprises the following steps: [0009] (1) antigen preparation: obtaining a PLGF-1 recombinant protein by expressing in Escherichia coil; [0010] (2) mice immunization: selecting 6-week-old BALB/C mice, and immunizing the selected mice by using the PLGF-1 recombinant protein obtained in Step (1) as an antigen; [0011] (3) culture of mouse myeloma cells 5P2/0: culturing myeloma cells SP2/0 from at least one of the mice in Step (2), and maintaining the cells in good growth status; [0012] (4) cell fusion: inducing cell fusion of splenic lymphocytes of mice in Step (2) and mouse myeloma cells SP2/0 in Step (3) by a cell fusion method using polyethylene glycol(PEG), and culturing the fused cells by using peritoneal macrophages of the BALB/C mice as feeder cells; [0013] (5) screening of hybridoma cells: culturing the culture obtained in Step (4), collecting a cell culture supernate for antibody identification, and screening for positive hybridoma cells; [0014] (6) cloning of hybridoma cells: cloning the positive hybridoma cells selected in Step (5) by limiting dilution method, and repeating the cloning several times until the positive rate of the wells for the hybridoma cells reaches 100%; [0015] (7) induction of ascites: injecting pristane to at least one of the BALB/C mice obtained in Step (2) intraperitoneally, inoculating with the positive hybridoma cells obtained in Step (6), and collecting ascites for centrifugation; and [0016] (8) purification of monoclonal antibody: purifying the monoclonal antibody in the ascites collected in Step (7) [0017] In another embodiment, the method specifically includes: [0018] (1) antigen preparation: obtaining the PLGF-1 recombinant protein by expressing in Escherichia coli, wherein the PLGF-1 recombinant protein contains 132 amino acids, and has a GenBank registration number of P49763.2; and optionally, the preparation of this protein is completed by Shanghai Puxin Biotechnology Co., Ltd.; [0019] (2) mice immunization: selecting 6-week-old BALB/C mice, and immunizing the mice by using the PLGF-1 recombinant protein obtained in Step (1) as an antigen, wherein each mouse is immunized through intramuscular injection on the inner thigh with 100 pg of the antigen peptide mixed with an adjuvant, and immunized again after 21 days, then used for cell fusion 3 days later from being booster-immunized for the third time; [0020] (3) culture of mouse myeloma cells SP2/0: culturing mouse myeloma cells SP2/0, and maintaining the cells in good growth status for hybridoma cell fusion; [0021] (4) cell fusion: using peritoneal macrophages of the BALB/C mice as feeder cells, seeding the BALB/C mice peritoneal macrophages into a 96-well culture plate and culturing for one day with a HAT medium containing 20% calf serum on the day before the cell fusion wherein a polyethylene glycol(PEG) cell fusion method is used; killing the mice prepared in Step (2) to obtain splenic lymphocytes; collecting the mouse myeloma cells SP2/0 in Step (3); mixing and centrifuging the above two cells, and mediating cell fusion with PEG; diluting the fused cells with a cell culture medium, and seeding them into the culture plate of the feeder cells, then culturing at 37°C in a 5% CO2 incubator; [0022] (5) screening of hybridoma cells: culturing the above-obtained culture, suctioning a supernate of the cell culture for antibody identification in case of the cell colonies growing to a suitable size, and screening for the positive clones; [0023] (6) cloning of hybridoma cells: cloning the positive hybridoma cells by a limiting dilution method, wherein the cells of a certain dilution density are seeded into a 96-well cell culture plate such that only one cell grows per well; taking a culture supernate from each well that has formed cell colonies for enzyme-linked immunosorbent assay (ELISA), and screening and identifying the positive clones; repeating the cloning several times until the positive rate of the wells for the hybridoma cells reaches 100%; [0024] (7) induction of ascites: injecting each of the BALB/C mice intraperitoneally with 0.5 ml of pristine one week before inoculation of the hybridoma cells; then inoculating each of the mice with 5x106 well-grown positive hybridoma cells, collecting and centrifuging the ascites 10 days later, and determining the antibody potency; and [0025] (8) purification of monoclonal antibody: purifying the monoclonal antibody in the ascites by using a Protein G affinity purification method.
[0026] Optionally, after Step (8), the method further includes: (9) subtype identification of the monoclonal antibody.
[0027] Further, an embodiment of the step (9) may be: diluting the purified monoclonal antibody appropriately and then assaying by a Serotec's immunoglobulin typing kit for mouse monoclonal antibody.
[0028] Furthermore, the operation in Step (9) is performed by strictly following the kit instructions, and the monoclonal antibody secreted by the hybridoma cell strain 9C1 belongs to the subtype IgG1, K, and is highly specific and sensitive to the PLGF-1 antigen.
[0029] The present invention has the following beneficial effects: the hybridoma cell 9C1 of the present invention secretes the PLGF-1 monoclonal antibody with high 30 efficiency and stability, and grows well after recovery from liquid nitrogen cryopreservation without decline in the antibody secretion; and the PLGF-1 monoclonal antibody of the present invention is highly specific and sensitive to the PLGF-1 antigen, and can be used in preparation of detection reagents for qualitative and quantitative detections in clinic and laboratory, with the detection results providing a laboratory diagnostic basis for clinical practice, so they both have good application prospects.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG. 1 shows an electrophoresis pattern of recombinant human PLGF-1 (rHuPLGF-1), where 1 indicates a protein Marker, and 2 and 3 indicate rHuPLGF-1 proteins.
[0031] FIG. 2 shows the sensitivity of a PLGF-1 monoclonal antibody detected by an indirect ELISA method [0032] FIG. 3 shows the accuracy of a PLGF-1 monoclonal antibody detected by a chem ilum inescence method.
THE EMBODIMENTS
[0033] The exemplary embodiments will be described in detail herein, and examples thereof are shown in the accompanying drawings. When the following description refers to the drawings, unless otherwise indicated, the same numbers in different drawings indicate the same or similar elements. The implementations described in the following exemplary embodiments are not all the implementations consistent with the present invention. On the contrary, they are simply examples of methods consistent with some aspects of the present invention, as specified in the appended claims.
[0034] The present invention will be further explained below in conjunction with the embodiments and the accompanying drawings. The following examples are only used to illustrate the present invention, rather than limit the implementation scope of the present invention.
[0035] Example 1 [0036] Preparation of a PLGF-1 monoclonal antibody includes the following steps: [0037] (1) antigen preparation: a PLGF-1 recombinant protein comprising 132 amino acids (GenBank registration number: P49763.2), which is obtained by expressing in Escherichia co/i., has a molecular weight of about 15 kDa as shown in the result of SDS-PAGE (FIG. 1), and its preparation has been completed by Shanghai Puxin Biotechnology Co., Ltd.; [0038] (2) mice immunization: 6-week-old BALB/C mice are selected and immunized by using the PLGF-1 recombinant protein obtained in Step (1) as an antigen, wherein each mouse is immunized through intramuscular injection on the inner thigh with 100 pg of the antigen peptide mixed with an adjuvant, and immunized again after 21 days, then used for cell fusion 3 days later from being booster-immunized for the third time; [0039] (3) culture of mouse myeloma cells SP2/0: mouse myeloma cells SP2/0 are cultured and maintained in good growth status for hybridoma cell fusion; [0040] (4) cell fusion: peritoneal macrophages of the BALB/C mice, which are used as feeder cells, are seeded into a 96-well culture plate and cultured for one day with a HAT medium containing 20% calf serum on the day before the cell fusion wherein a PEG cell fusion method is used; the mice prepared in Step (2) are killed to obtain splenic lymphocytes; the mouse myeloma cells SP2/0 in Step (3) are collected; the above two cells are mixed and centrifuged, then induced to fuse by PEG; the fused cells are diluted with a cell culture medium, seeded into the culture plate of the feeder cells, and then cultured at 37°C in a 5% CO2 incubator; [0041] (5) screening of hybridoma cells: the above-obtained culture are cultured, and a supernate of the cell culture is suctioned out for antibody identification and screening of positive clones when the cell colonies grow to a suitable size; [0042] (6) cloning of hybridoma cells: the positive hybridoma cells are cloned by a limiting dilution method, wherein the cells of a certain dilution density are seeded into a 96-well cell culture plate such that only one cell grows per well; a culture supernate is taken from each well that has formed cell colonies for enzyme-linked immunosorbent assay (ELISA), so as to screen and identify the positive clones; the cloning is repeated several times until the positive rate of the wells for the hybridoma cells reaches 100%; [0043] (7) induction of ascites: each of the BALB/C mice is injected intraperitoneally with 0.5 ml of pristine one week before inoculation of the hybridoma cells; then each of the mice is inoculated with 5x106 well-grown positive hybridoma cells; the ascites is collected and centrifuged 10 days later, and the antibody potency is determined; [0044] (8) purification of monoclonal antibody: the monoclonal antibody in the ascites is purified by using a Protein G affinity purification method; and [0045] (9) subtype identification of monoclonal antibody: the purified monoclonal antibody is diluted appropriately and then assayed by a Serotec's immunoglobulin typing kit for mouse monoclonal antibody strictly following the kit instructions, and the monoclonal antibody secreted by the hybridoma cell strain 9C1 belongs to the subtype IgGl, K, and is highly specific and sensitive to the PLGF-1 antigen.
[0046] The hybridoma cell strain 9C1 has been collected in China Center for Type Culture Collection (CCTCC) (Address: Wuhan University in Wuhan, China) on September 11, 2019 with the collection number of CCTCC NO: C2019216.
[0047] Example 2
[0048] In this example, the specificity and sensitivity of the PLGF-1 monoclonal antibody is detected by an indirect ELISA method including the following steps: [0049] (1) performing gradient dilution of a PIGF-1 recombinant protein (by double dilution method from 1000 ng/ml) with a carbonate buffer solution (CBS), then adding the diluted protein solutions to a 96-well ELISA plate (100 p1/well) and coating overnight at 4°C; [0050] (2) washing with PBST (phosphate buffer solution containing Tween-20) three times, 5 min for each time; [0051] (3) adding a blocking solution (PBS containing 5% bovine serum albumin) and blocking at 37°C for 1 h, then washing with PBST; [0052] (4) adding the antibody, which is gradient-diluted ( by double dilution method from 500 ng/ml) with PBS (phosphate buffer solution), 100 pl per well; using PBS as a negative control and incubating at 37°C for 1 h, then washing with PBST; [0053] (5) adding an HRP-labeled sheep anti-murine secondary antibody, 100 pl per well, and incubating at 37°C for 45 min, then washing with PBST; and [0054] (6) adding a TMB chromogenic solution and incubating at 37°C for 15 min, then ending with a sulfuric acid solution(2M) and reading with a microplate reader (450 nm).
[0055] The results are shown in FIG. 2 and Table 1. In this experiment, when the antibody concentration is 500 ng/ml, the recombinant protein at a concentration of 32.2 ng/ml has an OD value that is still shown as a clear positive signal. Tested for a single concentration of recombinant protein, 9C1 shows significant sensitivity at a concentration of 250 ng/ml.
[0056] Table 1 OD value Antibody concentration 500 250 125 62.5 31.25 0 (ng/mL) Recombinant protein concentration (ng/ml 1000 2.75 2.184 1.43 0.974 0.657 0.125 500 2.49 1.779 1.125 0.882 0.575 0.12 250 1.894 1.27 1.04 0.684 0.455 0.109 1.178 1.021 0.627 0.445 0.326 0.1 62.5 0.713 0.597 0.34 0.251 0.193 0.097 31.2 0.376 0.31 0.198 0.147 0.13 0.087 15.6 0.269 0.187 0.149 0.122 0.116 0.099 0 0.071 0.073 0.065 0.066 0.07 0.056 [0057] The accuracy of the PLGF-1 monoclonal antibody is detected by a chemiluminescence method including the following steps: [0058] (1) the 9C1 monoclonal antibody is labeled with biotin, and a PLGF commercial 10 antibody (Human PIGF Antibody (R&D systerms, catalog number AF-264-PB)) is labeled with acridinium ester; [0059] (2) magnetic beads are diluted with a diluent to 1 mg/ml; [0060] (3) the labeled antibodies are diluted with an antibody diluent to 500 ng/ml respectively; [0061] (4) the antibodies and the magnetic beads are loaded into a kit separately; [0062] (5) maternal blood samples are assigned with values using a Roche human placental growth factor (PIGF) electrochemiluminescence kit; [0063] (6) the kit is inserted into a fully automatic chemiluminescence instrument, and the blood samples are inserted into the sample slot; and [0064] (7) a one-step method is set for sample detection.
[0065] The results are shown in Table 2 and FIG. 3, and the resulting linear equation is y=1150.1x-2509.1, R2=0.9906.
[0066] Table 2
Sample Nos. plgf Detection results concentration (pg/ml) 6 1197 1336969 902.4 1112826 4 669.5 743862 3 500.7 604021 2 392.8 419783 1 368 383987 0 0 16169 [0067] According to the present invention, the indirect ELISA method includes that the hybridoma cell culture supernate obtained after the cell fusion reacts with a PLGF-1 antigen in a 96-well ELISA plate, a horseradish peroxidase-labeled sheep anti-murine antibody is added, and a light absorption value of each well is measured at a working wavelength of 450 nm, thus a hybridoma cell strain that secrets the anti-PLGF-1 monoclonal antibody is obtained by such screening and labeled as 9C1. After an immunological detection and screening method, the hybridoma cells that secret the anti-PLGF-1 monoclonal antibody are screened out, wherein the secreted antibody is the anti-PLGF-1 monoclonal antibody.
[0068] According to the present invention, the monoclonal antibody prepared for PLGF-1 provides higher accuracy, specificity and sensitivity for the detection of PLGF-1 protein, and the application of this antibody lays a foundation for functional research of PLGF-1 and the development of PLGF-1-based diagnostic reagents.
[0069] The present application has been described in detail in combination with specific embodiments and exemplary examples, but these descriptions cannot be understood as limitations on the present application. Those skilled in the art will understand that, without departing from the spirit and scope of the present application, the technical solution of the present application and its embodiments may be subjected to a variety of equivalent replacements, modifications or improvements, which all will fall within the scope of the present application. Therefore, the protection scope of the present application shall comply with the appended claims.
Claims (9)
- WHAT IS CLAIMED IS: 1. A hybridoma cell strain 9C1, which is collected in China Center for Type Culture Collection and has the collection number of CCTCC NO: C2019216.
- 2. A PLGF-1 monoclonal antibody, which is produced from the hybridoma cell strain 9C1 according to claim 1 that has the collection number of CCTCC NO: C2019216.
- 3. Use of the hybridoma cell strain 9C1 according to claim 1 in the preparation of a PLGF-1 monoclonal antibody.
- 4. Use of the PLGF-1 monoclonal antibody according to claim 2 in the preparation of an anti-human PLGF -1 detection reagent.
- 5. A detection reagent, comprising the PLGF-1 monoclonal antibody according to claim 2.
- 6. A method for preparation of the PLGF-1 monoclonal antibody according to claim 2, comprising the following steps: (1) antigen preparation: obtaining a PLGF-1 recombinant protein by expressing in Escherichia coli; (2) mice immunization: selecting 6-week-old BALB/C mice, and immunizing the selected mice by using the PLGF-1 recombinant protein obtained in Step (1) as an antigen; (3) culture of mouse myeloma cells SP2/0: culturing myeloma cells SP2/0 from at least one of the mice in Step (2), and maintaining the cells in good growth status; (4) cell fusion: inducing cell fusion of splenic lymphocytes of mice in Step (2) and mouse myeloma cells SP2/0 in Step (3) by a cell fusion method using polyethylene glycol(PEG), and culturing the fused cells by using peritoneal macrophages of the BALB/C mice as feeder cells; (5) screening of hybridoma cells: culturing the culture obtained in Step (4), collecting a cell culture supernate for antibody identification, and screening for positive hybridoma cells; (6) cloning of hybridoma cells: cloning the positive hybridoma cells selected in Step (5) by limiting dilution method, and repeating the cloning several times until the positive rate of the wells for the hybridoma cells reaches 100%; (7) induction of ascites: injecting pristane to at least one of the BALB/C mice obtained in Step (2) intraperitoneally, inoculating with the positive hybridoma cells obtained in Step (6), and collecting ascites for centrifugation; and (8) purification of monoclonal antibody: purifying the monoclonal antibody in the ascites collected in Step (7)
- 7. The method according to claim 6, comprising the following steps: (1) antigen preparation: obtaining the PLGF-1 recombinant protein by expressing in Escherichia coli, wherein the PLGF-1 recombinant protein contains 132 amino acids, and has a GenBank registration number of P49763.2; (2) mice immunization: selecting 6-week-old BALB/C mice, and immunizing the mice by using the PLGF-1 recombinant protein obtained in Step (1) as an antigen, wherein each mouse is immunized through intramuscular injection on the inner thigh with 100 pg of the antigen peptide mixed with an adjuvant, and immunized again after 21 days, then used for cell fusion 3 days later from being booster-immunized for the third time; (3) culture of mouse myeloma cells SP2/0: culturing mouse myeloma cells SP2/0, and maintaining the cells in good growth status for hybridoma cell fusion; (4) cell fusion: using peritoneal macrophages of the BALB/C mice as feeder cells, seeding the BALB/C mice peritoneal macrophages into a 96-well culture plate and culturing for one day with a HAT medium containing 20% calf serum on the day before the cell fusion wherein a polyethylene glycol(PEG) cell fusion method is used; killing the mice prepared in Step (2) to obtain splenic lymphocytes; collecting the mouse myeloma cells SP2/0 in Step (3); mixing and centrifuging the above two cells, and mediating cell fusion with PEG; diluting the fused cells with a cell culture medium, and seeding them into the culture plate of the feeder cells, then culturing at 37°C in a 5% CO2 incubator; (5) screening of hybridoma cells: culturing the above-obtained culture, suctioning a supernate of the cell culture for antibody identification in case of the cell colonies growing to a suitable size, and screening for the positive clones; (6) cloning of hybridoma cells: cloning the positive hybridoma cells by a limiting dilution method, wherein the cells of a certain dilution density are seeded into a 96-well cell culture plate such that only one cell grows per well; taking a culture supernate from each well that has formed cell colonies for enzyme-linked immunosorbent assay (ELISA), and screening and identifying the positive clones; repeating the cloning several times until the positive rate of the wells for the hybridoma cells reaches 100%; (7) induction of ascites: injecting each of the BALB/C mice intraperitoneally with 0.5 ml of pristine one week before inoculation of the hybridoma cells; then inoculating each of the mice with 5x106 well-grown positive hybridoma cells, collecting and centrifuging the ascites 10 days later, and determining the antibody potency; and (8) purification of monoclonal antibody: purifying the monoclonal antibody in the ascites by using a Protein G affinity purification method.
- 8. The method according to claim 6 or 7, after Step (8), the method further comprising: (9) subtype identification of the monoclonal antibody.
- 9. The method according to claim 8, wherein the step (9) specifically comprises: diluting the purified monoclonal antibody appropriately and then assaying by a Serotec's immunoglobulin typing kit for mouse monoclonal antibody.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/127828 WO2022099465A1 (en) | 2020-11-10 | 2020-11-10 | Hybridoma cell strain 9c1, plgf-1 monoclonal antibody, preparation method therefor and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202308366D0 GB202308366D0 (en) | 2023-07-19 |
| GB2616177A true GB2616177A (en) | 2023-08-30 |
Family
ID=81601865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2308366.0A Pending GB2616177A (en) | 2020-11-10 | 2020-11-10 | Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2616177A (en) |
| WO (1) | WO2022099465A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114874318B (en) * | 2022-06-13 | 2023-06-02 | 复旦大学附属中山医院 | NG-2 immunohistochemical antibody |
| CN115584346A (en) * | 2022-10-08 | 2023-01-10 | 厦门大学 | Mouse anti-human STC2 monoclonal antibody hybridoma cell strain, monoclonal antibody, preparation and application thereof |
| CN116732045A (en) * | 2023-07-13 | 2023-09-12 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | Anti-cat IgG monoclonal antibody and application thereof |
| CN117230020B (en) * | 2023-11-14 | 2024-01-26 | 中国农业科学院生物技术研究所 | G10 EPSPS monoclonal antibody hybridoma cell strain, antibody produced by same and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101184776A (en) * | 2005-03-24 | 2008-05-21 | 斯路姆基因公司 | Novel anti-plgf antibody |
| US20100015637A1 (en) * | 2008-06-18 | 2010-01-21 | Abbott Laboratories | Pigf-1 assay and kits and components thereof |
| CN102224419A (en) * | 2008-06-18 | 2011-10-19 | 雅培制药有限公司 | P/gf-1 companion diagnostic methods and products |
| CN102219854A (en) * | 2010-04-15 | 2011-10-19 | 苏州思坦维生物技术有限责任公司 | Monoclonal antibody of anti-human PIGF (placental growth factor) protein as well as preparation method and application thereof |
-
2020
- 2020-11-10 WO PCT/CN2020/127828 patent/WO2022099465A1/en active Application Filing
- 2020-11-10 GB GB2308366.0A patent/GB2616177A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101184776A (en) * | 2005-03-24 | 2008-05-21 | 斯路姆基因公司 | Novel anti-plgf antibody |
| US20100015637A1 (en) * | 2008-06-18 | 2010-01-21 | Abbott Laboratories | Pigf-1 assay and kits and components thereof |
| CN102224419A (en) * | 2008-06-18 | 2011-10-19 | 雅培制药有限公司 | P/gf-1 companion diagnostic methods and products |
| CN102219854A (en) * | 2010-04-15 | 2011-10-19 | 苏州思坦维生物技术有限责任公司 | Monoclonal antibody of anti-human PIGF (placental growth factor) protein as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Zeng, Zhaozhi et al, "Effect of anti-placenta growth factor antibody on endometriosis in rats", (Journal of Guangdong Pharmaceutical University), Vol. 32, No. 2, 30 April 2016, pp. 228-230 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022099465A1 (en) | 2022-05-19 |
| GB202308366D0 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2616177A (en) | Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof | |
| AU2008334976B2 (en) | Compositions and methods for early pregnancy diagnosis | |
| US8399207B2 (en) | Monoclonal antibodies against osteopontin | |
| EP3285071B1 (en) | Use of biomarker composition or kit for diagnosing still's disease and diagnostic method | |
| US20200088722A1 (en) | Pivka-ii measurement method, measurement reagent, and measurement kit | |
| CN102775473B (en) | The B cell epitope peptide fragment of human neutrophil gelatinase-associated lipocalin and its application | |
| US20230235028A1 (en) | Antibody against sars-cov-2, method for detecting sars-cov-2 using antibody and kit containing antibody | |
| EP2692735B1 (en) | Antibody reacting with native cochlin-tomoprotein (ctp) and method for measuring ctp using same | |
| CN109082413B (en) | Anti-human IgG monoclonal antibody, hybridoma cell strain and application thereof | |
| CN112358546B (en) | Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody and application thereof | |
| EP0606516B1 (en) | Anti-human ceruloplasmin monoclonal antibody | |
| CN114686441A (en) | Hybridoma cell strain capable of secreting tPAI-C monoclonal antibody and application thereof | |
| CN110079506B (en) | Monoclonal antibody of human serum fibrin ficolin-2 and application thereof | |
| CN117447601B (en) | Antibodies to porcine IgM, antibody compositions and uses thereof | |
| CN117447602B (en) | Antibodies to porcine IgM and uses thereof | |
| CN116731978B (en) | Hybridoma cell strain of anti-human hepatitis B surface antigen monoclonal antibody and preparation method of anti-human hepatitis B surface antigen monoclonal antibody | |
| CN115850459B (en) | Antibody targeting novel coronavirus N protein and application thereof | |
| CN114686442B (en) | Hybridoma cell strain and application thereof | |
| CN112410306B (en) | Double-antibody sandwich chemiluminescence immunoassay kit for detecting L-CRMP4 and application thereof | |
| WO2022149410A1 (en) | Biomarker for determining fertility, and determining method using same | |
| CN117624367A (en) | Anti-human CD141 protein rabbit monoclonal antibody and application thereof | |
| CN116121199A (en) | Brucella monoclonal antibody 6A5, application thereof and kit | |
| CN113563466A (en) | Monoclonal antibody preparation method, detection kit, detection method and application of monoclonal antibody of P.multocida antibody | |
| CN116731163A (en) | anti-ASFV pK205R protein monoclonal antibody, preparation and application thereof | |
| CN117487008A (en) | Anti-human Lin28A protein rabbit monoclonal antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 789A | Request for publication of translation (sect. 89(a)/1977) |
Ref document number: 2022099465 Country of ref document: WO |